Sports Medicine

, Volume 33, Issue 6, pp 395–399 | Cite as

Marijuana as Doping in Sports

  • Daniel R. Campos
  • Mauricio Yonamine
  • Regina L. de Moraes Moreau
Leading Article

Abstract

A high incidence of positive cases for cannabinoids, in analyses for doping control in sports, has been observed since the International Olympic Committee (IOC) included them in the 1989 list of prohibited drugs under the title of classes of prohibited substances in certain circumstances. Where the rules of sports federations so provide, tests are conducted for marijuana, hashish or any other cannabis product exposure by means of urinalysis of 11-nor-delta-9-tetrahydro-cannabinol-9-carboxylic acid (carboxy-THC) the main metabolite of delta-9-tetrahydrocannabinol (THC). Concentrations >15 ng/mL (cut-off value) in confirmatory analytical procedures are considered doping. Cannabis is an illicit drug in several countries and has received much attention in the media for its potential therapeutic uses and the efforts to legalise its use.

Studies have demonstrated that the use of cannabinoids can reduce anxiety, but it does not have ergogenic potential in sports activities. An increase in heart rate and blood pressure, decline of cardiac output and reduced psychomotor activity are some of the pharmacological effects of THC that will determine a decrease in athletic performance. An ergolytic activity of cannabis products has been observed in athletes of several different sport categories. In Brazil, analyses for doping control in sports, performed in our laboratories, have detected positive cases for carboxy-THC in urine samples of soccer, volleyball, cycling and other athletes.

It is our intention to discuss in this article some points that may discourage individuals from using cannabis products during sports activities, even in the so-called permitted circumstances defined by the IOC and some sports federations.

References

  1. 1.
    Verroken M. Drug use and abuse in sport. J Clin Endocrinol 2001; 14(1): 1–23Google Scholar
  2. 2.
    Mottram DR. Banned drugs in sports. Sports Med 1999; 27(1): 1–10PubMedCrossRefGoogle Scholar
  3. 3.
    International Olympic Committee. Prohibited classes of substances and prohibited methods. Lausanne: International Olympic Committee, 1999Google Scholar
  4. 4.
    Drumer OH. The forensic pharmacology of drugs of abuse. London: Arnold, 2001Google Scholar
  5. 5.
    Frank M, Rosenthal E. Marijuana growers guide. Berkeley (CA): And/Or Press, 1978Google Scholar
  6. 6.
    Reinhardt VED, Midio AF. Características botânicas,químicas e produtos obtidos da Cannabis. Rev Farm Bioquim Univ Sao Paulo 1993; 29(2): 55–61Google Scholar
  7. 7.
    Carter J. Government eases restrictions on Marinol [online]. Available from URL: http://www.ahemp.org/Marinol_III.html [Accessed 2002 Jun 25]
  8. 8.
    Wall ME, Brine DR, Pit CG, et al. Identification of delta-9-te-trahydrocannabinol and metabolites in man. J Am Chem Soc 1972; 94(24): 8579–81PubMedCrossRefGoogle Scholar
  9. 9.
    Porter AC, Felder CC. The endocannabinoid nervous system: unique opportunities for therapeutic intervention. Pharmacol Ther 2001; 90: 45–60PubMedCrossRefGoogle Scholar
  10. 10.
    Pertwce RG. Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther 1997; 74(2): 129–80CrossRefGoogle Scholar
  11. 11.
    Adams IB, Martin BR. Cannabis: pharmacology and toxicology in animals and humans. Addiction 1996; 91(11): 1585–614PubMedCrossRefGoogle Scholar
  12. 12.
    Johansson EK, Hollister LE, Halldin MM. Urinary elimination half-life of delta-1-tetrahydrocannabinol-7-oic acid in heavy marijuana users after smoking. NIDA Res Monogr 1989; 95: 457–8PubMedGoogle Scholar
  13. 13.
    Kelly P, Jones RT. Metabolism of tetrahydrocannabinol in frequent and infrequent marijuana users. J Anal Toxicol 1992; 16(4): 228–35PubMedGoogle Scholar
  14. 14.
    Huestis MA, Mitchell JM, Cone EJ. Detection times of marijuana metabolites in urine by immunoassay and GC-MS. J Anal Toxicol 1995; 19(6): 443–9PubMedGoogle Scholar
  15. 15.
    Huestis MA, Mitchell JM, Cone EJ. Urinary excretion profiles of 11-nor-delta-9-carboxy-tetrahydrocannabinol in humans after single smoke doses of marijuana. J Anal Toxicol 1996; 20(6): 441–52PubMedGoogle Scholar
  16. 16.
    Caplan YH. Workplace testing. In: Karch SB, editor. Drug abuse handbook. Boca Raton (FL): CRC Press, 1998: 738Google Scholar
  17. 17.
    Mareck-Engelke U, Geyer H, Schanzer W. Misuse of cannabinoids in high level competitions. Deutsche Zeitschrift fur Sportmedizin 2001; 52(10): 280–4Google Scholar
  18. 18.
    Eichner ER. Ergolitic drugs in medicine and sports. Am J Med 1993; 94(2): 205–11PubMedCrossRefGoogle Scholar
  19. 19.
    Wennig R. Threshold values in toxicology: useful or not? Forensic Sci Int 2000; 113: 323–30PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2003

Authors and Affiliations

  • Daniel R. Campos
    • 1
  • Mauricio Yonamine
    • 1
  • Regina L. de Moraes Moreau
    • 1
  1. 1.Laboratory of Analytical Toxicology, College of Pharmaceutical SciencesUniversity of São PauloSão PauloBrazil

Personalised recommendations